Daclatasvir interactions
Full monograph for DaclatasvirCheck it against another medicine
Medicines
181 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Apalutamide | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the… | 6 sources — open the full entry |
| Bosentan Monohydrate | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasone | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Carbamazepine | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the… | 6 sources — open the full entry |
| Cenobamate | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Ceritinib | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by…2 documented mechanisms | 5 sources — open the full entry |
| Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Colchicine | Major | Excretion | Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the serum concentrations of colchicine. The mechanism involves enhanced… | 78 sources — open the full entry |
| Dexamethasone | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by…2 documented mechanisms | 5 sources — open the full entry |
| Dexamethasone + Levofloxacin | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Dexamethasone + Neomycin + Glacial Acetic Acid | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphate | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Dexamethasone + Tobramycin | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Efavirenz | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Eluxadoline | Major | Metabolism | Coadministration with inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of eluxadoline… | 8 sources — open the full entry |
| Enzalutamide | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the… | 6 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Fosphenytoin Sodium | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the… | 6 sources — open the full entry |
| Gatifloxacin + Dexamethasone | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Itraconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Ketoconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleovera | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapine | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Lopinavir + Ritonavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Lorlatinib | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Mifepristone | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Mifepristone + Misoprostol | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Morphine Sulfate | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of morphine and its risk of adverse effects, including… | 7 sources — open the full entry |
| Moxifloxacin Hydrochloride + Dexamethasone | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Nelfinavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Nirmatrelvir + Ritonavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Phenobarbital | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the… | 6 sources — open the full entry |
| Phenytoin Sodium | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the… | 6 sources — open the full entry |
| Posaconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Primidone | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the… | 6 sources — open the full entry |
| Rabeprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Relugolix | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the… | 2 sources — open the full entry |
| Relugolix + Estradiol + Norethindrone | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the… | 2 sources — open the full entry |
| Rifampicin | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the… | 6 sources — open the full entry |
| Rifampicin + Isoniazid | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the… | 6 sources — open the full entry |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the… | 6 sources — open the full entry |
| Sotorasib | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Tucatinib | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Venetoclax | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter. | 5 sources — open the full entry |
| Vonoprazan + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Voriconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
Conditions
Conditions in which Daclatasvir needs care, as documented in this source.
Fibrosis
MajorIn clinical studies, HCV genotype 3-infected patients with cirrhosis receiving daclatasvir in combination with sofosbuvir for 12 weeks demonstrated reduced sustained virologic response (SVR12) rates. In addition, in hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfected patients, the use of daclatasvir may cause a reactivation of the HBV. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. It is recommended to test all patients for evidence of prior HBV infection before initiating therapy with daclatasvir. Close monitoring for signs and symptoms of hepatitis flare or HBV reactivation is recommended during HCV treatment with daclatasvir and during after treatment follow-up. Consider appropriate management for patients with HBV infection as clinically indicated.
1 source
- "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb (2015):
Therapeutic duplication
Drug classes that overlap with Daclatasvir, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
ns5a inhibitors
The recommended maximum number of medicines in the 'NS5A inhibitors' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'NS5A inhibitors' category.
Example product in the source data (US market): Ombitasvir/paritaprevir/ritonavir
ns5a inhibitors
The recommended maximum number of medicines in the 'NS5A inhibitors' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'NS5A inhibitors' category.
Example product in the source data (US market): Zepatier
ns5a inhibitors
The recommended maximum number of medicines in the 'NS5A inhibitors' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'NS5A inhibitors' category.
Example product in the source data (US market): Dasabuvir/ombitasvir/paritaprevir/ritonavir
ns5a inhibitors
The recommended maximum number of medicines in the 'NS5A inhibitors' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'NS5A inhibitors' category.
Example product in the source data (US market): Sofosbuvir/velpatasvir/voxilaprevir